Skip to main content
S&P 5007,611.15+0.34%DOW52,061.59-0.06%NASDAQ26,162.26+0.70%BTC$76,078.00-0.98%ETH$2,408.58-1.03%GOLD$4,370.50+0.87%OIL$102.27-3.36%
Smart Investors Daily
AL

NASDAQ · ALGS

Aligos Therapeutics, Inc.

Healthcare · Biotechnology

$4.99

Down-$0.05 (-1.00%)

Updated Sep 16, 2026, 6:16 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
43.26M
P/E ratio
-0.84
Dividend yield
0.00%
52-week range
$3.98 – $8.97
Volume
34.49K
Avg. volume
68.51K

Price performance

ALGS price history

1M range · 20 trading sessions · Daily adjusted prices

ALGS closed at $4.99 after 20 trading sessions, down 26.18% for the selected period.

Last close
$4.99
Period change
-26.18%
Period low
$4.99
Period high
$7.51
Daily close
View OHLC price history
ALGS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$5.04$5.445$4.82$4.9934.49K
Sep 14, 2026$5.17$5.27$5.02$5.0428.02K
Sep 11, 2026$5.39$5.5019$5.14$5.2237.04K
Sep 10, 2026$5.38$5.48$5.21$5.3346.07K
Sep 9, 2026$5.79$6.02$5.4101$5.5033.02K
Sep 8, 2026$6.21$6.3396$5.62$5.7664.24K
Sep 4, 2026$6.16$6.21$6.02$6.2120.29K
Sep 3, 2026$6.22$6.48$6.07$6.2242.08K
Sep 2, 2026$6.15$6.64$6.01$6.2155.41K
Sep 1, 2026$5.76$6.22$5.61$6.09101.64K
Aug 31, 2026$6.83$6.83$5.86$5.8698.92K
Aug 28, 2026$7.025$7.10$6.6401$6.9139.07K
Aug 27, 2026$7.44$7.495$6.8201$7.0780.52K
Aug 26, 2026$7.37$7.72$7.04$7.5168.95K
Aug 25, 2026$6.93$7.5377$6.71$7.4793.64K
Aug 24, 2026$6.61$7.00$6.40$6.9333.22K
Aug 21, 2026$6.48$6.7985$6.40$6.6752.33K
Aug 20, 2026$6.77$7.0055$6.35$6.4462.5K
Aug 19, 2026$6.74$7.085$6.67$6.8977.34K
Aug 18, 2026$6.50$6.84$6.4818$6.76110.13K

Latest ALGS news

The latest Smart Investors Daily articles mentioning ALGS.

Stock researchCompany · Overview

ALGS research

Overview

Company profile and research snapshot.

Company profile

Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$3.00
Implied upside
—
Analysts
10
ALGS recent ratings
DateFirmRatingTarget
May 28, 2026Lake StreetBuy—
May 21, 2026Cantor FitzgeraldOverweight—
Mar 26, 2026WestPark CapitalBuy—
Mar 11, 2026HC Wainwright & Co.Buy—
Jan 7, 2026UBSBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Cantor Global Healthcare Conference. Cantor Global Healthcare Conference Fireside Chat on Wednesday, September 9, 2026 at 8:00am ET The presentation will premiere at the time listed above

Yahoo · Aug 6, 2026

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the second quarter 2026. “Our team has continued to execute on our key strategic priorities to advance our pipeline this year,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, Pres

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By